Search Orphan Drug Designations and Approvals
-
Generic Name: | Bexarotene | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Targretin | ||||||||||||||||
Date Designated: | 06/18/1999 | ||||||||||||||||
Orphan Designation: | Treatment of cutaneous T-cell lymphoma. | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Eisai, Inc. 300 Tice Blvd Woodcliff Lake, New Jersey 07677 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | Bexarotene |
---|---|---|
Trade Name: | Targretin | |
Marketing Approval Date: | 12/29/1999 | |
Approved Labeled Indication: | Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. | |
Exclusivity End Date: | 12/29/2006 | |
Exclusivity Protected Indication* : | ||
-